Rai Shinya, Tanizawa Yoshinori, Terasawa Tomoko, Tajimi Masaomi, Ideue Ryuichi, Burlison Helen, Milloy Neil, Simpson Amber, Taipale Kaisa-Leena, Jen Min-Hua, Segall Grace, Goebel Benjamin, Kiran Amit
Department of Hematology and Rheumatology, Kindai University Hospital, Osakasayama, Japan.
Eli Lilly and Company, Indianapolis, IN, USA.
Future Oncol. 2025 Sep 7:1-12. doi: 10.1080/14796694.2025.2555165.
The objective of this study was to describe the disease management landscape for patients with mantle cell lymphoma (MCL) in Japan.
We conducted a cross-sectional survey with retrospective data capture of physicians and their consulting patients between March and December 2022. Physicians completed patient record forms in a 1:2 ratio: one patient receiving first-line (1 L) treatment and two patients with relapsed/refractory disease, one of whom must have received and discontinued a Bruton's tyrosine kinase inhibitor (BTKi).
Sixty-seven patients were included - most were male (74.6%) and diagnosed with classical MCL (76.1%), with a mean age of 69.4 years and median time since MCL diagnosis of 18.0 months. The most common initial symptom was painless swelling in the neck, armpit, stomach, or groin (72%). Overall, patients had a "complete response" to 1 L (32/67 [47.8%]) therapy and "partial response" to 2 L (24/45 [53.3%]) therapy. Side effects were less commonly reported with BTKi than with chemotherapy. The most important physician-perceived treatment goal was to "minimize impact on patient's daily life" or "tumor response" for patients receiving BTKi or chemotherapy, respectively.
Patients' disease was generally well-managed by their physicians; however, improvements in efficacy, safety, and quality of life are still needed.
本研究的目的是描述日本套细胞淋巴瘤（MCL）患者的疾病管理情况。
我们于2022年3月至12月进行了一项横断面调查，回顾性收集医生及其咨询患者的数据。医生以1:2的比例填写患者记录表：一名接受一线（1L）治疗的患者和两名复发/难治性疾病患者，其中一名患者必须接受并停用布鲁顿酪氨酸激酶抑制剂（BTKi）。
共纳入67例患者，大多数为男性（74.6%），诊断为经典型MCL（76.1%），平均年龄69.4岁，自MCL诊断以来的中位时间为18.0个月。最常见的初始症状是颈部、腋窝、腹部或腹股沟无痛性肿胀（72%）。总体而言，患者对1L治疗有“完全缓解”（32/67 [47.8%]），对2L治疗有“部分缓解”（24/45 [53.3%]）。与化疗相比，BTKi的副作用报告较少。医生认为最重要的治疗目标分别是对于接受BTKi或化疗的患者“尽量减少对患者日常生活的影响”或“肿瘤反应”。
患者的疾病总体上得到了医生的良好管理；然而，仍需要提高疗效、安全性和生活质量。
